arrow
M

Michael J. Morris

university of maryland baltimore
H指数:90
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer

SULT2A1基因位点与Abiraterone清除率的关联性:Alliance A031201研究——一项比较Enzalutamide与Enzalutamide联合Abiraterone治疗转移性去势抵抗性前列腺癌的随机III期研究

2025-12-050
OAAI
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

SPARC:标准化前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描分析与报告共识:一项德尔菲分析

2025-09-130
PREAI
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

[177Lu]Lu-PSMA-617与雄激素受体途径抑制剂变化的PSMAfore 3期试验在未接受紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的最终总生存期和安全性分析

2025-07-170
OAAI
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

进展性转移性去势抵抗性前列腺癌患者 [177Lu]Lu-PSMA-617的健康相关生活质量、疼痛和症状性骨骼事件 (PSMAfore): 一项开放标签、随机、3期试验

2025-05-260
PRE
Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B

联合激素疗法对18F-Piflufolastat PET/CT在前列腺癌患者中诊断性能的影响:OSPREY队列B的亚组分析

2025-05-040
OAAI
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

下降的前列腺特异性抗原水平与接受[177Lu]Lu-PSMA-617治疗的三期VISION试验中转移性去势抵抗性前列腺癌患者临床结局的关联

2024-12-010
OAAI
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

对患有生物化学复发和晚期前列腺癌的男性实施循证策略: 来自美国前列腺癌会议2024的共识建议

CANCER
IF5.1
2024-12-010
PRE
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

给予雄激素受体途径抑制剂的转移性去势抵抗性前列腺癌患者的克隆造血和临床结局 (联盟A031201)

2024-09-180
PRE
Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore

在PSMAfore研究中,[177Lu]Lu-PSMA-617与ARPI对转移性去势抵抗性前列腺癌患者血液学影响的变化比较

2024-09-010
PRE
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

177Lu-PSMA-617与雄激素受体途径抑制剂治疗的变化对紫杉烷初治的进行性转移性去势抵抗性前列腺癌患者 (PSMAfore): 一项3期随机对照试验

LANCET
IF88.5
2024-09-014
PRE
Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer

与前列腺癌骨活检组织成功基因组分析相关的临床、影像和技术因素

2024-08-010
PRE
Single- cell analysis of treatment- resistant prostate cancer: Implications of cell state changes for cell surface antigen- targeted therapies
2024-07-054
OAAI
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial
CANCER
IF5.1
2024-06-211
OAAI